

The Use of Magnetic Field for the Reduction of Inflammation: A Review of the History and Therapeutic Results

Christina L. Ross; Benjamin S. Harrison, PhD

ABSTRACT

Interest in magnetic field (MF) therapy has increased rapidly in recent years as research shows that this noninvasive, cost-effective modality might be safer than drugs and surgical procedures for reduction of inflammation. Inflammation is a signal-mediated response to tissue invasion by pathogens or toxins or to injury or physical stresses. The immune response plays a pivotal role in reaction to insult, which triggers an inflammatory response almost immediately. Commonly, pharmaceuticals are used to suppress inflammation, although some evidence

shows that suppressing inflammation can hinder wound healing. Immunological studies show that MF therapy, even low-intensity MF, interacts with cells and tissues, and the use of MF as an alternative or complement to currently prescribed therapies could lead to a faster reduction in the inflammatory response. This review highlights past and present outcomes in bioelectromagnetic therapies and some of the more promising findings on the effect that MF therapy plays in inflammatory responses. (*Altern Ther Health Med.* 2013;19(2):47-54.)


Christina L. Ross is a PhD candidate in the Department of Energy Medicine at Akamai University in Hilo, Hawaii and a research fellow at Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. **Benjamin S. Harrison, PhD**, is associate professor of regenerative medicine at Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Corresponding author: Benjamin S. Harrison, PhD
E-mail address: bharriso@wakehealth.edu

Interest in magnetic field (MF) therapy has increased in the past several years, as researchers have suggested its use as an alternative or complementary treatment to control the inflammatory response (Figure 1).¹⁻³ Immunological studies show that MF, even low-intensity MF, interacts with cells and tissues.⁴⁻⁷ In particular, interest in the effect of MF on phagocytotic cells has attracted a lot of attention due to the role that extremely low-frequency, electromagnetic fields (ELF-EMF) play in decreasing the growth rate of tumors.⁸⁻¹⁰ Research examining the effect of a whole-

body magnetic field on cancer patients has shown that MF therapy has overall beneficial effects, particularly with respect to improved immune status and postoperative recovery.¹¹

Figure 1. The Increase in Number of Peer-reviewed Published Articles Showing Interest in Magnetic Field Therapies (from 1985 to 2012)



For many years it was thought that electromagnetic-field (EMF) exposure would cause only harmful effects in the body, but it is now understood that the amount of energy (field strength or amplitude) and the frequency of the field is what determines whether MF is harmful, therapeutic, or benign.¹² In particular, ionizing radiation has been shown to cause harmful effects by breaking the electron bonds that hold molecules like DNA together.^{13,14} Fields capable of generating ionizing fields include alternating current (AC) that is produced by power lines, electrical wiring, and electrical equipment. Some epidemiological studies have suggested that an increased risk of cancer is associated with magnetic-field exposure near electrical power lines.^{12,15,16}

The energy in nonionizing radiation, however, is not strong enough to break ion bonds in atoms and molecules.^{17,18} Depending on the frequency and amplitude, beneficial non-ionizing EMF has been reported to decrease calcium-transport alterations in human lymphocytes,^{19,20} support natural killer cells fighting cancer and viruses,²¹⁻²⁷ modulate traumatic brain injury,²⁸ and reduce postoperative infections as well as bacterial and viral-related inflammatory responses that are major complications in today's medicine.²⁹⁻³¹ Tissue-permeating interventions, such as pulsed electromagnetic fields (PEMF), increase healing rates immediately after injury³ due to their ability to quickly restore the equilibrium between free radicals and antioxidants as they work to stop the cascade of inflammatory progression and biochemical degradation in the traumatized tissue.³² PEMF therapies not only potentially restore equilibrium in reactive oxygen species (ROS) related to free radical/antioxidant chemistry, they also induce currents that stabilize cytosolic Ca²⁺ that is activated by oxidative stress, upregulate classes of protective and restorative gene loci, and down-regulate dysregulatory and apoptotic gene loci.³

ELF-EMF has been reported to prohibit bacterial growth and improve immune response against bacterial infection.³³ Antibiotics have proved to be very effective in the treatment of bacterial infections, but the way in which antibiotics are administered orally and distributed systemically throughout the body can create a lag time between the administration of the drug and its absorption at the site of insult. The time it takes an antibiotic to reach therapeutic levels can be significantly longer if the vascular system is compromised. During the time it takes a pharmaceutical to reach the site of injury, MF treatment can be applied and can penetrate even poorly vascularized tissue. Pending the delivery of an antibiotic, bacteria can multiply³⁴; therefore developing treatments that can stimulate the efficacy of the immune system while waiting for antibiotics to take effect, could prevent septic shock. An urgent need also exists to address the lack of effective treatments to meet the increasing public-health burden caused by multidrug-resistant bacteria, in particular gram-negative bacteria.³⁵

Inflammation initializes as a response to prevent the spread of damaging agents to nearby tissues, dispose of cell debris and pathogens, and set the stage for the repair and

regenerative process.³⁶ The regeneration of tissues and organs is highly dependent on the ability of cells to keep inflammation under control so that the acute inflammatory response does not become chronic. Acute inflammation allows the tissue to regenerate through cell proliferation, while chronic inflammation continuously destroys the tissue after it has been rebuilt. A stable inflammatory response depends on the release of proper amounts and types of immune inflammatory and anti-inflammatory cells and their cytokines.³⁷

When inflammation subsides, the damaged tissue may not be completely repaired, depending on the severity of the inflammation and the type of tissue involved. In minor inflammation of the skin, for example, the tissue is capable of complete regeneration, whereas in cardiac tissue, regeneration is more limited, and the damaged cells are often replaced by scar tissue.^{29,31} It is during the time in which an acute-phase inflammatory response becomes chronic that the need for a noninvasive treatment is so critical. After the inflammatory response has been initiated and the immune system activated, adding pharmacological treatments—either orally, by injection, or topically, all of which have damaging side effects—can easily lead to further harm such as gastrointestinal trouble,³⁸ yeast overgrowth,³⁹ and anaphylactic or anaphylactoid reactions.⁴⁰ MF therapies, however, have shown few, if any, side effects in the treatment of inflammatory responses.⁴¹

The immune response is a signal-mediated reaction to tissue invasion by pathogens or toxins or to injury or physical stresses. It is triggered by signal transduction, which is the conversion of cell information from one form to another.⁴² Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their environment is the basis of development, tissue repair, and immunity as well as normal tissue homeostasis.

In addition to fighting pathogens, the immune system monitors the health of cells and disposes of cells that have been injured or killed.⁴³ When microbes such as bacteria or viruses breach epithelia and enter the tissues or blood stream, they are attacked by specialized lymphocytes called phagocytes and by several plasma proteins.^{42,43} Immediately following microbial invasion or tissue trauma, certain lymphocytes known as monocytes leave the blood and mature into macrophages that enter the tissue around the injured or infected site. Macrophages are widely distributed, bone-marrow-derived leukocytes that phagocytose foreign particles. They either stimulate inflammation or suppress it by releasing chemical signals that alter the behavior of other cells.⁴⁴ Macrophages are second only to hepatocytes in the amount of protein molecules they release after phagocytosing antigens and other particulates as well as destroying pathogens such as bacteria.^{45,46} Resident macrophages are migratory cells that are found in connective tissues and in every organ in the body.⁴⁷ They migrate to extravascular sites

of infection by binding to endothelial adhesion molecules in response to chemical attractants that are produced when they encounter microbes.


Macrophages are activated by binding to the invading pathogens, the result of which is the release of locally produced cytokines.⁴⁸ Cytokines are inflammatory proteins that react to tissue injury and infection and are synthesized in a wide range of biological actions in various tissues.⁴⁹⁻⁵¹ They are cell-signaling messengers that have specific effects on the interactions between cells, on communication between cells, or on the behavior of cells. The signaling mechanism of the proinflammatory cytokine cell is responsible for the initiation of the inflammatory response. Immune responses can be broken down into individual signal-transduction events through which changes in the extracellular environment elicit altered gene expression at the cellular level.^{52,53}

Because EMF is able to influence cell communication, it is capable of attenuating inflammation even at genomic levels (Figure 2).^{54,55} Errors in cellular information processing are responsible for inflammatory diseases,⁵⁶ autoimmunity,⁵⁷ irritable bowel syndrome,⁵⁸ and diseases such as cancer,⁵⁹ diabetes,⁶⁰ and even Alzheimer's disease.⁶¹ Inflammation is also a key characteristic of pain and edema.⁶² Research has shown that certain inflammatory-cell signals are involved in the initiation and persistence of pathologic pain through activated nociceptive sensory neurons.⁶³

Current therapies used to reduce inflammation can cause adverse side effects. Treatments such as nonsteroidal, anti-inflammatory drugs (NSAIDs), used primarily to treat inflammation and associated pain, are designed to effect a specific biochemical target; however, they have an analgesic-dose ceiling and can cause gastric bleeding, renal toxicity, cardiovascular concerns, and occasional central nervous system effects, including loss of short-term memory and decreased attention span.⁶⁴ In addition, NSAIDs can cause many other side effects, the most common being nausea, vomiting, diarrhea, constipation, decreased appetite, rash, dizziness, headache, and drowsiness. They can also cause fluid retention, leading to edema. The most serious side effects of prescription NSAIDs are kidney failure, liver failure, ulcers and prolonged bleeding after an injury or surgery, heart attacks, and strokes.⁶⁵

Other options for treating inflammation include heat therapy, which may be applied to the body's surface or to deep tissues. Hot packs, infrared heat, paraffin (heated wax) baths, and hydrotherapy are inexpensive and easily accessible methods of treatment, but too much heat can cause burns.⁶⁶ Cold therapy is dosed in the form of ice packs in direct contact with the skin. When ice is applied, it lowers the skin temperature and helps to reduce swelling and inflammation. Ice can also numb nerve endings, stopping the transfer of impulses to the brain that register as pain. Although readily

Figure 2. (a) Shows cells after 3 hours of induction of LPS-cells aggregate to amplify signaling for TNF- α , IL-1 α , IL-1 β and IL-6. (b) Shows cells after 1 hour of exposure to PEMF; cell signaling is dampened, and cells become less inflamed.



available, if not closely monitored, cold therapies can cause frostbite or cell necrosis, nerve damage, reflex sympathetic dystrophy, tissue death, amputation, loss of use of a limb, and complex regional pain syndrome.⁶⁷⁻⁶⁹ In contrast to these standards of treatment, MF therapies have few if any side effects and have a major advantage in their affordability over both pharmaceuticals and the cost of surgery.^{41,70,71} Other benefits include ready availability, ease of localized application, and indefinite shelf life.⁴¹

BIOPHYSICS

Bioelectromagnetics is the study of how living organisms interact with electromagnetic fields (EMFs). This interaction takes place because all living matter is made of electrons, atoms, ions, and molecules. Faraday's Law explains the interchange between electricity and magnetism—that is, how voltage can be generated by changing the magnetic environment and how a magnetic field can be altered by changing voltage. Faraday's Law can be applied to electrical currents that already exist in the body (heart, brain, etc). These currents are capable of producing magnetic fields outside the body⁷² and can be measured by electrocardiograph (ECG), electroencephalograph (EEG), and magnetoencephalography (MEG), which is a technique for mapping brain activity by recording magnetic fields produced by electrical currents occurring naturally in the brain. These fields can be affected by exogenous EMF stimulation,⁷² as can organs and cells in the body.⁴ Research shows that the cell membrane is one of the main locations where applied EMF acts on the cell.^{73,74} EMF at the membrane's outer surface can alter the ligand-receptor interactions,⁷⁵ also known as mechanically gated ion channels.⁷⁶ A low-frequency EMF passes unobstructed through living tissue, and in some cases, weak EMFs have resonant patterns that are close to the frequencies of Ca^{2+} , Na^+ , and other ions.⁷³

MAGNETIC FIELD THERAPIES

In 1982, a PEMF device was approved by the US Food and Drug Administration (FDA) for bone repair, although it remains widely unused due to physicians' misunderstanding and lack of knowledge concerning the treatment.⁷⁷ PEMF therapeutic devices can be applied in two different ways, either by capacitive or inductive coupling. In capacitive coupling, no contact occurs with the body, whereas direct coupling requires the placement of opposing electrodes in direct contact with the surface of the skin of the targeted tissue.⁷¹ Inductive coupling does not require electrodes to be in direct contact with the skin because it produces a field (see Faraday's Law of Induction) that emanates in all directions.

Research has shown that therapeutic applications at ELF-EMF (1-300 Hz) levels stimulate the immune system by suppressing inflammatory responses at the cell-membrane level.⁷⁸ Double-blind, placebo-controlled clinical trials⁷⁹ show that MF passes through the skin into the body's conductive tissue,⁷⁹⁻⁸¹ reducing pain and the onset of edema shortly after trauma.^{82,83} Where edema is already present, treatment

exhibits significant anti-inflammatory effects.⁸⁴ In a study of the effect of MF therapy on arthritis, 3 hours of exposure to a 50-Hz magnetic field revealed that experimentally induced inflammation in rats was significantly inhibited as a result.⁸⁵ Strong beneficial effects have also occurred using 75-Hz frequency, MF treatment in patients suffering from fractures of the ankle joints.⁸⁶ In a randomized, double-blind, sham-controlled clinical study, low-frequency PEMF therapy at 0.1 to 64 Hz was shown to improve mobility, pain, and fatigue in fibromyalgia patients.⁸⁷

MF-field treatment has been shown to enhance health and wellness by increasing blood flow⁸⁸ and aiding the efficiency of DNA repair.⁸⁹ In addition, researchers have suggested that the use of therapeutic EMFs can protect the myocardium from ischemia reperfusion injury⁹⁰ and can treat neurodegenerative disorders such as Alzheimer's disease.⁹¹ Depending on the dose (field strength and frequency) and duration of treatment, the EMF exposure can be harmful or induce a cytoprotective cellular response.⁹² At 75 Hz (1.5 mT), EMFs display anti-inflammatory effects in human osteoarthritis synovial fibroblasts, by modulating inflammatory and anti-inflammatory parameters.⁹³ At 50 Hz (1 mT), ELF-EMF modulates chemokine production and keratinocyte growth through inhibition of the NF κ B signaling pathway, and thus, may inhibit inflammatory processes.⁹⁴ A 27.12 MHz, radio-frequency PEMF was shown to modulate an inflammatory cytokine after traumatic brain injury,⁹⁵ while repeated 915-MHz irradiation could cause DNA breaks in renal and liver cells in rats but did not affect the cell genome at the higher extent compared to the basal damage.⁹⁶

Findings from preclinical and clinical studies suggest that psychiatric illness, particularly major depressive disorder (MDD), is associated with inflammatory processes.⁹⁷ High-frequency (53 GHz) radiation was used to treat 53 neurotically depressed patients. Full recovery was observed in over 50% of cases, considerable improvement in over 40%, and some improvement in over 8%.⁹⁸ at 42.2, 51.8, and 65 GHz. In addition to decreased pain, edema, and infection, other therapeutic benefits include an increase in ATP production,¹⁰⁰ normalization of cellular-membrane potentials,¹⁰¹ and oxygenation of tissues and removal of toxins from the cells,¹⁰² with few if any side effects.

Medical risks associated with posttraumatic stress disorder (PTSD) have an underlying inflammatory pathology suggesting that inflammation contributes to these health declines.¹⁰³ In one study, 12 patients with PTSD and major depression underwent PEMF treatment of either 1 Hz or 5 Hz as an adjunct to antidepressant medications. Seventy-five percent of the patients had a clinically significant, antidepressant response after treatment, and 50% had sustained that response at a 2-month follow-up. Comparable improvements were seen in anxiety, hostility, and insomnia.¹⁰⁴

While pharmaceutical approaches commonly are used to suppress the inflammatory response, evidence exists that suppressing inflammation can hinder wound healing.^{105,106}

Table 1. Examples of Different Magnetic Therapies Applied in the Identified Research Studies to Treat Inflammatory-related Conditions

Condition	B or Freq*	Treatment Duration	Treatment Number	Key Finding
Alzheimer's ⁹¹	5–8 Hz	30 min	2x daily for 9 mo	Significant improvement of cognitive function
Arthritis ¹	60 Hz	90 min	3x daily until condition improves	Reduction of pain and inflammation
Back pain ¹⁰⁷	64 Hz	16 min	Until pain stopped	Statistically significant potential for reducing pain
Bacterial infection ³³	50 Hz	4–6 h	1x	Increased immune response against bacteria
Cancer (breast, colon, and prostate tumors) ⁸	0.1 Hz–114 kHz	60 min	2x/wk for 4 mo	Significant decrease in size of tumor with tumor-specific frequencies
Carpal tunnel syndrome ¹⁰⁸	20 Hz	4 h	Daily for 2 mo	Statistically significant short- and long-term pain reduction
Chronic bronchitis ¹⁰⁹	30 mT	15–20 min/d	15x for 6 mo	Effective treatment in patients suffering from chronic bronchitis when coupled with standard drug therapies
Cognitive function ¹¹⁰	900 MHz	2 h/wk	55 wk	Significant reduction in cognitive impairment in rats
Edema ⁸⁴	70 mT	15–30 min	6x in 3 h	Significant reduction of acute edema
Fibromyalgia ⁸⁷	0.1–64 Hz	30 min	2x d/3 wk	Improved function, decreased pain and fatigue, and improved global status in FM patients
Gastroduodenitis ¹¹¹	100 Hz	6–10 min	8–10x for 2 wk	Elimination of gastro-esophageal and duodenogastral refluxes for 77% of treated patients compared to 29% of controls
Glial cells ¹¹²	900 MHz	15 min daily	2–10 d	Induction of glial reactivity and biochemical modifications in the rat brain
Mastitis ^{103,113}	10–25 Hz	60 min	2x/wk for 3 mo	Significant reduction in postop inflammation
Multiple sclerosis ¹¹⁴	1–25 Hz	2–24h/d	Up to 5 wk	Significant alleviation of symptoms with PEMF device
Migraine headache ¹¹⁵	27.12 Hz	1 h/d	5 d/wk for 2 wk	Effective, short-term intervention for migraine but not for tension headaches
Nerve regeneration ¹¹⁶	2 Hz/0.3mT	1 h/d	10 d	Suggested indirect influence on regeneration for pre- and postinjury exposure with PEMF
Neuritis ^{116,117}	7.5 picoT	20 min	10–12x until vision improved	Production of beneficial effects in 93% of patients suffering from nerve problems
Oral surgery preop ¹¹⁸	5mT/30Hz	30 min	3–5 d prior to surgery	Significant reduction in inflammation in clinical trials
Osteoarthritis ¹¹⁹	10 G–25 G/5–24 Hz	9 h	18x in 1 mo	Rapid improvements of immunological indices and alleviation of symptoms
Pain and edema ¹²⁰	1mT or 5 mT	6 h/d	90 d	Significant aid to clinical recovery
Post traumatic stress disorder ¹⁰⁴	1Hz or 5Hz	15 min daily	10 consecutive d for 20–30 d	A clinically significant antidepressant response for 75% of patients
Rheumatoid arthritis ¹²¹	30 mT	30 min	15–20x/mo	Reduction of pain in chronic-pain populations
Septic shock ¹²²	50 Hz/2mT	6 h	1x	Greater sensitization of <i>E coli</i> to antibiotics
Skin ulcers ¹²³	75 Hz/2.7 mT	4 hr/d	for 3 mo	Positive effects but only in small lesions
Tendonitis ¹²⁴	30 mT	60 min	10–20x for 8 wk	Significant beneficial effects
Whiplash ¹²⁵	64 Hz	8 min	4x in a 2-wk period	Considerable and statistically significant pain reduction
Wound healing in diabetic mice ¹²⁶	15 Hz	8 h/d	24 d	Significant reduction in postoperative pain for a decrease in the need for analgesic resolve

Abbreviations: B = magnetic field; G = gauss; T = tesla; Hz = hertz; 1 mT = 10 gauss

Studies show that PEMF treatments can promote cell activation and endothelial-cell proliferation through the cell membrane. Endothelial cells contribute to vasculogenesis. Neovascularization is essential for the survival of growing, injured, and ischemic tissue.¹²⁷

ELF levels can increase the rate of formation of epithelial cells in partially healed wounds and also quicken the healing time of skin wounds that were surgically created on the backs of rats.¹²⁸ Fields at 15 Hz were used to significantly accelerate wound healing in diabetic mice.¹²⁹ The electric field of a wound has been measured as 177 ± 14 mV/mm immediately after trauma. Field lines point away from the wound in all directions instantaneously after injury, and these field lines are the first signals indicating skin damage. This electric field is generated at the outer surface of the epidermis by the outward flow of the current of injury. An equal and opposite current must flow within the multilayered epidermis to generate an intraepidermal field within the negative pole at the wound site.¹²⁸ These skin wounds have electrical potentials that can be stimulated by ELF-EMF to aid in the healing process by dedifferentiating cells near the wound, thereby accelerating cell proliferation.⁷⁸ Pennington et al¹³⁰ used a double-blind study among active-duty, military personnel, treating 50 grade-1 and grade-2 ankle sprains with one 30-minute, postinjury PEMF therapy, and reported a statistically significant difference in the outcomes, promoting reduced time loss in these military personnel.¹³⁰

Various types of magnetic fields exist, such as static and time-varying as well as continuous and pulsed, with a wide range of frequencies. Most doses of time-varying and pulsed MF therapies run between 1 Hz and 75 Hz, with ranges of intensity between 1 microtesla (μ T) and 250 millitesla (mT), though significant results have been seen with high-frequency treatments. Durations of treatments range between 10 minutes and 48 hours with the number of treatments varying between 10 sessions spaced over several weeks up to three months, depending on the condition (Table 1).

Though many trials have been run in vitro and in vivo, clinical dosimetry needs further research. Of important note is the lack of standardized nomenclature and experimental protocols. Like most pharmaceuticals, where dosages vary from patient to patient, MF therapies are dose dependent per patient and also per individual tissue(s).^{131,132} It has been suggested that at least ten different dosing parameters should be required for all practitioners using MF therapies.¹³³ These parameters would include specifying (1) the targeted tissue(s), (2) the site of MF application, (3) the distance of magnetic surface from targeted tissue(s), (4) the MF strength, (5) the material composition of the magnet, (6) the magnet's dimensions (size, shape, and volume), (7) the magnetic polar configuration, (8) the magnetic support device, and (9) the frequency and duration of MF application. Contraindications include pregnancy or pacemaker implants.

CONCLUSION


The use of MF for anti-inflammatory and wound-healing applications is well known.^{1,134,135} Because MF can be applied almost immediately after injury and can penetrate even poorly vascularized tissue, the benefits of using MF as a complement or alternative to anti-inflammatory treatments can be advantageous. Growing interest in this noninvasive, low-cost therapy is stimulating a lot of research in MF treatments. Studies show no discomfort occurs and few known risks are associated with the use of MF therapy. The presence of implanted metal does not appear to affect the therapeutic ability of MF.⁸¹ When compared to the standard of care, MF therapies are a viable complement or alternative to treating inflammation in most patients.

REFERENCES

- Ganesan K, Gengadharan A, Balachandran C, Manohar B, et al. Low frequency pulsed electromagnetic field—a viable alternative for arthritis. *Indian J Exp Biol*. 2009;47(12):939-948.
- Markov M. Expanding use of pulsed electromagnetic field therapies. *Electromagn Biol Med*. 2007;26(3):257-274.
- Gordon G. Designed electromagnetic pulsed therapy: clinical applications. *J Cell Physiol*. 2007;212(3):579-582.
- Blank M, Goodman R. Do electromagnetic fields interact directly with DNA? *Bioelectromagnetics*. 1997;18(2):111-115.
- Markov M, Nindl G, Haslewood C, Cuppen J. Interactions between electromagnetic fields and immune system: possible mechanism for pain control. *Bioelectromagnetics Current Concepts*. 2006; Springer; 1 edition 213-225.
- Zimmerman J, Pennison M, Brezovich I, et al. Cancer cell proliferation is inhibited by specific modulation frequencies. *Br J Cancer*. 2012;106(2):307-313.
- Saino E, Fassina L, Van Vlierberghe S, et al. Effects of electromagnetic stimulation on osteogenic differentiation of human mesenchymal stromal cells seeded onto gelatin cryogel. *Int J Immunopathol Pharmacol*. 2011;24(1 suppl 2):1-6.
- Barbault A, Costa F, Bottger B, et al. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. *J Exp Clin Cancer Res*. 2009;28:51-60.
- Costa F, de Oliveira A, Meirelles R, et al. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. *Br J Cancer*. 2011;105:640-648.
- Zimmerman Z, Pennison M, Brezovich I, et al. Cancer cell proliferation is inhibited by specific modulation frequencies. *Br J Cancer*. 2012;106:307-313.
- Zlatnik E, Kapkina N, Zaderin V, Zakora G. Immunocorrective effect of alternating magnetic field in the postoperative period in malignant bladder cancer. *Vopr Onkol*. 2001;47(3):312-314.
- Administration OsaH. Extremely Low Frequency (ELF) Radiation. <http://www.osha.gov/SLTC/elfradiation>. Retrieved February 15, 2012.
- Buonanno M, Toledo S, Azzam E. Increased frequency of spontaneous neoplastic transformation in progeny of bystander cells from cultures exposed to densely ionizing radiation. *PLoS One* 2011;6(6):e21540.
- Mobbs S, Muirhead C, Harrison J. Risks from ionising radiation: an HPA viewpoint paper for safe grounds. *J Radiol Prot*. 2011;31(3):289-307.
- Organization WH. Electromagnetic fields and public health. *WHO fact sheet on electromagnetic hypersensitivity*. Retrieved February 15, 2012. <http://www.who.int/mediacentre/factsheets/fs296/en/index.html>.
- Feychting M, Ahlbom A, Kheifets L. EMF and health. *Annu Rev Public Health*. 2005;26:165-189.
- Tenforde T, Kaune W. Interaction of extremely low-frequency electric and magnetic fields with humans. *Health Phys*. 1987;53:585-606.
- Ng K-H. Non-ionizing radiations—sources, biological effects, emissions and exposures. *Proceedings of the International Conference on Non-Ionizing Radiation at UNITEN ICNIR2003 Electromagnetic Fields and Our Health*. 2003. Available at <http://www.who.int/peh-emf/meetings/archive/en/keynote3ng.pdf>.
- Wallaczek J. Electromagnetic field effects on cells of the immune system: the role of calcium signaling. *FASEB J*. 1992;6:3177-3185.
- Kindzelskii A, Petty H. Ion channel clustering enhances weak electric field detection by neutrophils: apparent roles of SKP96365-sensitive cation channels and myeloperoxidase trafficking in cellular responses. *Eur Biophys J*. 2005;35(1):1-26.
- Cadossi R, Emilia G, Torelli G. Lymphocytes and pulsing magnetic field. In: Marino AA, ed. *Modern Bioelectricity*. New York, NY: Marcel Dekker, Inc; 1988a.
- Cadossi R, Iverson R, Hentz V, Zucchini R, et al. Effect of low-frequency low-energy pulsing electromagnetic fields on mice undergoing bone marrow transplantation. *Intl J Immunopath Pharm*. 1988b;1:57-62.

23. Cossarizza A, Monti D, Bersani F, Cantini M, et al. Extremely low-frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects. *Biochem Biophys Res Commun*. 1989a;160:692-698.
24. Cossarizza A, Monti D, Bersani F, Paganelli R, et al. Extremely low-frequency pulsed electromagnetic fields increase interleukin-2 (IL-2) utilization in IL-2 receptor expression in mitogen-stimulated human lymphocytes from old subjects. *FEBS* 1989b;248:141-144.
25. Cossarizza A, Monti D, Sola P, Moschini G, et al. DNA repair after irradiation in lymphocytes exposed to low-frequency pulsed electromagnetic fields. *Radiat Res*. 1989c;118:161-168.
26. Mi Y, Sun C, Yao C, et al. Effect of steep pulsed electric fields on the immune response of tumor-bearing Wistar mice. *Sheng Wu Yi Xue Gong Cheng Xue Za Zhi*. 2007;24(2):253-256.
27. Traitcheva N, Angelova P, Radeva M, Berg H. ELF fields and photooxidation yielding lethal effects on cancer cells. *Bioelectromagnetics*. 2003;24(2):148-150.
28. Rasouli J, Lekhraj R, White NM, et al. Attenuation of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injury. *Neurosci Lett*. 2012;519(1):4-8.
29. Darouiche R. Device-associated infections: a macroproblem that starts with microadherence. *Clin Infect Dis*. 2001;33(9):1567-1572.
30. Harris L, Richards R. Staphylococci and implant surfaces: a review. *Injury*. 2006;37(2):S3-S14.
31. Saakatian-Elahi M, Teysou R, Vanhems P. Staphylococcus aureus, the major pathogen in orthopaedic and cardiac surgical site infections. *Int J Surg*. 2008;6(3):238-245.
32. Han J, Shuvaev VV, Muzykantov VR. Targeted interception of signaling reactive oxygen species in the vascular endothelium. *Ther Deliv*. 2012;3(2):263-276.
33. Akan Z, Aksu B, Tulunay A, Bilsel S, Inhan-Garip A. Extremely low-frequency electromagnetic fields affect the immune response of monocyte-derived macrophages to pathogens. *Bioelectromagnetics*. 2010;31(8):603-612.
34. Wenke J, Guelcher SA. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. *Expert Opin Drug Deliv*. 2011;8(12):1555-1569.
35. Freire-Moran L, Aronsson B, Manz C, et al. ECDC-EMA Working Group. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now. *Drug Resist Updat*. 2011;14(2):118-124.
36. Janeway C, Travers P, Walport M, Shlomchik M. *Immunobiology*. 6th ed. New York, NY: Garland Science Publishing; 2005:19.
37. Kedzierska K, Crowe S. Cytokines and HIV-1: interactions and clinical implications. *Antivir Chem Chemother*. 2001;12(3):133-150.
38. Lawrence P. Conservative treatment of aortic graft infection. *Semin Vasc Surg*. 2011;24(4):199-204.
39. Mueller R, Bergvall K, Benschneider E, Bond R. A review of topical therapy for skin infections with bacteria and yeast. *Vet Dermatol*. 2012;23(4):330-e362.
40. Peroni D, Sansotta N, Bernardini R, et al. Perioperative allergy: clinical manifestations. *Int J Immunopathol Pharmacol*. 2011;24(3 suppl):S69-74.
41. Rubik B. Bioelectromagnetics and the future of medicine. *Admin Rad J*. 1997;16(8):38-46.
42. Gomperts B, Kramer I, Tatham P. *Signal Transduction*. 2nd ed. Burlington, MA: Elsevier; 2009.
43. Karavitis J, Kovacs E. Macrophage phagocytosis: effects of environmental pollutants, alcohol, cigarette smoke, and other external factors. *J Leukoc Biol*. 2011;90(6):1065-1078.
44. Porta C, Riboldi E, Totaro M, Strauss L, Sica A, Mantovani A. Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. *Immunotherapy*. 2011;3(10):1185-1202.
45. Laskin D, Pendino K. Macrophages and inflammatory mediators in tissue injury. *Annu Rev Pharmacol Toxicol*. 1995;35:655-677.
46. Laskin D, Laskin J. Role of macrophages and inflammatory mediators in chemically induced toxicity. *Toxicology*. 2001;160(1-3):111-118.
47. Janeway C, Medzhitov R. Lipoproteins take their toll on the host. *Curr Biol*. 1999;9(23):R879-882.
48. Kawczyk-Krupka A, Sieron A, Shani J, Czuba Z, et al. Biological effects of extremely low-frequency electromagnetic fields on stimulated macrophages J774.2 in cell culture. *Electromag Biol Med*. 2002;21:141-153.
49. Aggarwal B, Vilcek J. Comparative analysis of the structure function of TNF-alpha and TNF-beta. *Immunol Ser*. 1992;56:61-78.
50. Akira S, Hirano T, Tani T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). *FASEB J*. 1990;4:2860-2867.
51. Benveniste E. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. *Amer J of Phys*. 1990;269:C1-C16.
52. Ivashkiv L. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. *Eur J Immunol*. 2011;41(9):2477-2481.
53. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. *Trends Immunol*. 2009;30:383-391.
54. Binhi V, Savin A. Effects of weak magnetic fields on biological systems: physical aspects. *Phys-Usp*. 2003;45(3):259-291.
55. Girgert R, Hanf V, Emons G, Gründker C. Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fields. *Bioelectromagnetics*. 2010;31(3):237-245.
56. Ohashi P. T-cell signalling and autoimmunity: molecular mechanisms of disease. *Nat Rev Immunol*. 2002;2(6):427-438.
57. Fujimoto M, Sato S. B-cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. *J Dermatol Sci*. 2007;46(1):1-9.
58. Mayer E. Clinical practice. Irritable bowel syndrome. *N Engl J Med*. 2008;358(16):1692-1699.
59. Zhang Q, Chen G, Lin X, Quian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. *Cell Res*. 2007;17:89-99.
60. Zhang J, Hupfield C, Taylor S, Olefsky J, et al. Insulin disrupts B-adrenergic signalling to protein kinase A in adipocytes. *Nature*. 2005;437(569-573).
61. Tan Z, Beiser A, Vasan R, Roubenoff R, et al. Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. *Neurology*. 2007;68:1902-1908.
62. Li W, Guo T, Li X, Kingery W, et al. Fracture induces keratinocyte proliferation and expression of pro-nociceptive inflammatory mediators. *Pain*. 2010;151(3):843-852.
63. Zhang J, An J. Cytokines, Inflammation and pain. *Int Anesthesiol Clin*. 2007;45(2):27-37.
64. Zullino DF, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. *Br J Clin Pharmacol*. 2005;59(1):118-119.
65. Brennan F, Carr D, Cousins M. Pain management: a fundamental human right. *Anesthesia Anal*. 2007;105(1):205-221.
66. Moritz A, Henriques F. Studies of thermal injury II. The relative importance of time and surface temperature in the causation of cutaneous burns. *Am J Pathol*. 1947;23:695-720.
67. Graham C, Stevenson J. Frozen chips: an unusual cause of severe frostbite injury. *Br J Sports Med*. 2000;34(5):382-383.
68. MacAuley D. Ice therapy: how good is the evidence? *Int J Sports Med*. 2001;22(5):379-384.
69. McMaster W. A literary review on ice therapy in injuries. *Am J Sports Med*. 1977;5(3):124-126.
70. Bassett C. Fundamental and practical aspects of therapeutic uses of pulsed electromagnetic fields (PEMFs). *Crit Rev Biomed Eng*. 1989;17:451-529.
71. Trock D. Electromagnetic fields and magnets: investigational treatment for musculoskeletal disorders. *Rheum Dis Clin North Am*. 2000;26(1):51-62.
72. Becker R, Marino A. *Electromagnetism and Life*. Albany, NY: State University of New York Press; 1982.
73. Bawin S, Adey W, Sabbott I. Ionic factors in release of 45-Ca²⁺ from chicken cerebral tissue by electromagnetic fields. *Proc Natl Acad Sci USA*. 1978;75:6314-6318.
74. Romeo S, Zeni L, Sarti M, et al. DNA electrophoretic migration patterns change after exposure of Jurkat cells to a single intense nanosecond electric pulse. *PLoS One*. 2011;6(12):e28419.
75. Funk R, Monsees T. Effect of electromagnetic fields on cells: physiological and therapeutical approaches and molecular mechanisms of interaction. *Cell, Tissues, Organs*. 2006;182(2):59-78.
76. Irmak M. Multifunctional Merkel Cells: their roles in electromagnetic reception, finger-print formation, Reiki, epigenetic inheritance and hair form. *Medical Hypothesis*. 2010;75:162-168.
77. Bassett A, Carpenter D, Ayrapetyan S. Therapeutic uses of electric and magnetic fields in orthopedics. *Biological Effects of Electric and Magnetic Fields: Beneficial and Harmful Effects*. II. San Diego, CA: Academic Press; 1994:13-48.
78. O'Connor M, Bentall R, Monahan J. Emerging Electromagnetic Medicine conference proceedings. New York, NY: Springer-Verlag; 1990.
79. Stiller M, Pak G, Shupack J, Thaler S, et al. A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double-blind placebo-controlled clinical trial. *Br J Dermatol*. 1992;27:147-154.
80. Hannan C, Liang J, Allison J, Pantazis C, et al. Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. *Anticancer Research*. 1994;14:1521-1524.
81. Traina G, Romanini L, Benazoo F, Cadossi V. Use of electric and magnetic stimulation in orthopaedics and traumatology: consensus conference. *J Ortho Trauma*. 1998;24(1):1-31.
82. Rohde C, Chiang A, Adipoju O, Casper D, Pilla A. Effects of pulsed electromagnetic fields on IL-1b and post operative pain: a double-blind, placebo-controlled pilot study in breast reduction patients. *Plast Reconstr Surg*. 2009;125:1620-1629.
83. Chalidis B, Sachinis N, Assiotis A, Maccauro G. Stimulation of bone formation and fracture healing with pulsed electromagnetic fields: biologic responses and clinical implications. *Int J Immunopathol Pharmacol*. 2011;24(1 suppl 2):17-20.
84. Morris C, Skalak T. Acute exposure to a moderate strength static magnetic field reduces edema formation in rats. *Am J Physiol Heart Circ Physiol*. 2007;294:H50-H57.
85. Mizushima Y, Akaoka I, Nishida Y. Effects of magnetic field on inflammation. *Experientia*. 1975;31(12):1411-1412.
86. Gromak G, Lacin G. Evaluations of the efficacy of using a constant magnetic field in treatments of patients with traumas. *Electromagnetic Therapies of Injuries and Diseases of the Support-Motor Apparatus*. 1987(International Collection of Papers, Riga, Latvia: Riga Medical Institute):88-95.
87. Sutbeyaz S, Sezer N, Koseoglu F, Kibar S. Low-frequency pulsed electromagnetic field therapy in fibromyalgia: a randomized, double-blind, sham-controlled clinical study. *Clin J Pain*. 2009;25(8):722-728.
88. Gmitrov J, Ohkubo C, Okano H. Effect of 0.25 T static magnetic field on microcirculation in rabbits. *Bioelectromagnetics*. 2002;23:224-229.
89. Chow J, Tung W. Magnetic field exposure enhances DNA repair through the induction of DnaK/J synthesis. *FEBS Lett*. 2000;478:133-136.

90. DiCarlo A, Farrell J, Litovitz T. Myocardial protection conferred by electromagnetic fields. *Circulation (suppl 1)*. 1999;99:813.
91. Arendash G, Sanchez-Ramos J, Mori T, et al. Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. *J Alzheimers Dis*. 2010;19:191.
92. Osera C, Fassina L, Amadio M, et al. Cytoprotective response induced by electromagnetic stimulation on SH-SY5Y human neuroblastoma cell line. *Tissue Eng Part A*. 2011;17(19-20):2573-2582.
93. Ongaro A, Varani K, Masieri F, et al. Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. *J Cell Physiol*. 2012;227(6):2461-2469.
94. Vianale G, Reale M, Amerio P, Stefanachi M, Di Luzio S, Muraro R. Extremely low frequency electromagnetic field enhances human keratinocyte cell growth and decreases proinflammatory chemokine production. *Br J Dermatol*. 2008;158(6):1189-1196.
95. Rasouli J, Lekhraj R, White N, et al. Attenuation of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injury. *Neurosci Lett*. 2012;Apr 5. [Epub ahead of print].
96. Trosić I, Pavićić I, Milković-Kraus S, Mladinić M, Zeljezić D. Effect of electromagnetic radiofrequency radiation on the rats' brain, liver and kidney cells measured by comet assay. *Coll Antropol*. 2011;35(4):1259-1264.
97. Krishnadas R, Cavanagh, J. Depression: an inflammatory illness? *J Neurol Neurosurg Psychiatry*. 2012; Mar 15. [Epub ahead of print].
98. Morozov G, Antropov I, Asanova L, Shkanov S. Treatment of neurotic depression with a help of extremely high frequency electromagnetic radiation. *Zh Nevropatol Psikhiatr Im S S Korsakova*. 1996;96(6):28-31.
99. Gapeyev A, Mikhailik E, Chemeris N. Anti-inflammatory effects of low-intensity extremely high-frequency electromagnetic radiation: Frequency and power dependence. *Bioelectromagnetics*. 29(3):197-206.
100. Cheng N, Van Hoof H, Bockx E, Hoogmartens MJ, et al. The effects of electric currents on ATP generation, protein synthesis, and membrane transport in rat skin *Clin Orthop*. 1982;171:264-272.
101. Markov M. Expanding Use of Pulsed Electromagnetic Field Therapies. *Electromagn Biol Med*. 2007;26(3):257-274.
102. Houghton P, Campbell K. Choosing an adjunctive therapy for the treatment of chronic wounds. *Ostomy Wound Manage*. 1999;45(8):43-52.
103. Smith A, Conneely K, Kilaru V, et al. Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2011;156B(6):700-708.
104. Rosenberg P, Mehndiratta R, Mehndiratta Y, Wamer A, et al. Repetitive transcranial magnetic stimulation treatment of comorbid posttraumatic stress disorder and major depression. *J Neuropsychiatry Clin Neurosci*. 2002;14:270-276.
105. McFarland M, Funk H, Paluch A, Zhou M, et al. Differences in wound healing in mice with deficiency of IL-6 vs IL-6 receptor. *J of Immun*. 2010;184(12):7219-7228.
106. Ishida Y, Kondo T, Takayasu T, Iwakura Y, et al. The essential involvement of cross-talk between IFN-gamma and TGF-beta in skin wound healing process. *J of Immun*. 2004;172:1848-1855.
107. Lee P, Kim Y, Lim Y, Lee C, et al. Efficacy of pulsed electromagnetic therapy for chronic lower back pain: a randomized, double-blind, placebo-controlled study. *J Int Med Res*. 2006;34(2):160-167.
108. Weintraub M, Cole S. A randomized controlled trial of the effects of a combination of static and dynamic fields on carpal tunnel syndrome. *Amer Acad Pain Med*. 2008;9(5):493-504.
109. Iurlov V, Eksareva T, Dolodarenko V. The efficacy of the use of low-frequency electromagnetic fields in chronic bronchitis. *Voen Med Zh*. 1989;3:35-36.
110. Nittby H, Grafström G, Tian D, Malmgren L, et al. Cognitive impairment in rats after long-term exposure to GSM-900 mobile phone radiation. *Bioelectromagnetics*. 2008;29(3):219-232.
111. Bukanovich O, Khan M, Chistova L, Sheliapina V, et al. Sinusoidally-modulated currents in the therapy of chronic gastroduodenitis in children. *Von Kurortol Fizioter Lech Fiz Kult*. 1996;2:22-26.
112. Brillaud E, Piotrowski A, de Seze R. Effect of an acute 900MHz GSM exposure on glia in the rat brain: a time-dependent study. *Toxicology*. 2007;238(1):23-33.
113. Navaratil L, Hlavaty V, Landsingerova E. Possible therapeutic applications of pulsed magnetic fields. *Cas Lek Cesk*. 1993;132(9):590-594.
114. Lappin M, Lawrie F, Richards T, Kramer E. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. *Altern Ther Health Med*. 2003;9(4):38-48.
115. Sherman R, Acosta N, Robso L. Treatment of migraine headaches with pulsing electromagnetic fields: A double blind, placebo controlled study. *Headache*. 1999;39(8):567-575.
116. Sisken B. Nerve regeneration: implicaiton for clinical application of electrical stimulation. Paper presented at: First World Congress for Electricity and Magnetism in Biology and Medicine; June 1992; Orlando, FL.
117. Sandyk R. Treatment with AC pulsed electromagnetic fields normalizes the latency of the visual evoked response in a multiple sclerosis patient with optic atrophy. *Int J Neurosci*. 1998 93(3-4):239-250.
118. Hillier-Kolarov V, Pekaric-Nadj N. PEMF therapy as an additional therapy for oral diseases. *EuroBioelectromag Assoc*. 1992(1st Congress):23-25.
119. Hulme J, Robinson V, DeBie R, Wells G, et al. Electromagnetic fields for the treatment of osteoarthritis. *Cochrane Review*. 2002;1(CD003523).
120. Dallari D. Effects of pulsed electromagnetic stimulation on patients undergoing hip revision prostheses: A randomized prospective double-blind study. *Bioelectromagnetics*. 2009;30(6):423-430.
121. Shupak N. Therapeutic uses of pulsed magnetic field exposure. *Radio Science Bulletin*. 2003;307 (December):9-32.
122. Gaafar E, Hanafy M, Tohamy E, Ibrahim M. Stimulation and control of E. coli by using an extremely low-frequency magnetic field. *Romanian J. Biophys*. 2006;16(4):283-296.
123. Jeran M. PEMF stimulation of skin ulcers of venous origina in humans: preliminary report of a double blind study. *Bioelectromagnetics*. 1987;6(2):181-188.
124. Binder A. Pulsed electromagnetic field therapy of persistent rotator cuff tendinitis. *Lancet*. 1984;8379:695-698.
125. Thuilea C, Walzlb M. Evaluation of electromagnetic fields in the treatment of pain in patients with lumbar radiculopathy or the whiplash syndrome. *NeuroRehabilitation*. 2002;17(1):63-67.
126. Man D. Effect of permanent magnetic field on postoperative pain and wound healing in plastic surgery. *Proceedings of Second World Congress for Electricity and Magnetism in Biology and Medicine*. 1997.
127. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*. 1997;275(5302):964-967.
128. Nuccitelli R, Nuccitelli P, Ramlatchan S, Sanger R, Smith P. Imaging the electric field associated with mouse and human skin wounds. *Wound Repair Regen*. 2008;16(3):432-441.
129. Callaghan M, Chang E, Seiser N, Arabi S, et al. Pulsed electromagnetic fields accelerate normal and diabetic wound healing by increasing endogenous FGF-2 release. *Plast Reconstr Surg*. 2007;121(1):130-141.
130. Pennington G, Danley DL, Sumko MH, Bucknell A, Nelson JH. Pulsed non-thermal, high frequency electromagnetic energy (DIAPULSE) in the treatment of Grade 1 and Grade 2 ankle sprains. *Mil Med*. 1993;158:101-104.
131. Adey W. Physiological signaling across cell membranes and cooperative influences of extremely low frequency electromagnetic fields. *Biological Coherence and Response to External Stimuli*. 1988; Springer-Verlag: New York, NY:148-170.
132. Sisken B, Walker J. Therapeutic aspects of electromagnetic fields for soft-tissue healing. *Amer Chem Soc: Washington, DC*. 1995 10(1):277-285.
133. Colbert A, Markov M, Souder J. Static magnetic field therapy: dosimetry considerations. *J Altern Complem Medicine*. 2008;14(5):577-582.
134. Selvam R, Kalaivani G, Narayana K, Gangadharan A, et al. Low frequency and low intensity pulsed electromagnetic field exerts its antiinflammatory effects through restoration of plasma membrane calcium ATPase activity. *Life Sci*. 2007;80:2403.
135. Messerli M, Graham, D. Extracellular electrical fields direct wound healing and regeneration. *Biol Bull*. 2011;221(1):79-92.



MASTER CHINESE HERBAL MEDICINE
through our
DISTANCE LEARNING PROGRAM

FOR HEALTHCARE PRACTITIONERS OF ALL TRADITIONS:

- **Treat a wider range of conditions more effectively.**
- **Taught by experienced Western practitioners who easily translate the Chinese herbal system.**
- **Learn at your own pace on your schedule.**

Learning herbs and formulas, theory, and diagnostic methods are presented together in each class. Emphasis is placed on clinical applications.

California Provider #357/NCCAOM Provider #ACHB-069
Listen to audio samples on our website at:
www.ich-herbschool.com
~ 800-736-0182 ~

California Provider #357 NCCAOM-Provider #ACHB-069
California allows a maximum of 25 CEU distance learning units per renewal period.

Free!

audio samples and ordering information online:
ich-herbschool.com